Tornado Licenses 82 Rapamycin Derivatives for Trials

D

Dr. Joan Mannick on InsideTracker's Channel

Anti-AgingMedical

Quotes From Source

“Tornado in-licensed 82 new rapamycin derivatives from Novartis.”

Story of claim

Tornado Therapeutics has secured 82 novel rapamycin derivatives from Novartis to explore safer, more effective mTOR inhibitors aimed at extending human health span.

  • Goal: Extend human health span through safer and more effective mTOR inhibitors.
  • Proof: Rapamycin derivatives may help in developing therapies that extend the human health span.
  • Nuances:
    • Involvement of multiple stakeholders in the development and testing
    • Encouragement to participate in clinical trials for conclusive results
  • Impact on Life: These trials may lead to breakthroughs in aging therapies, potentially improving quality of life as people age.

Investments

  • Price:
  • Time:
  • Effort:

Risks

Potential risks involved in trial participation; other companies exploring similar derivatives.

Get Started 🚀

  • Consider enrolling in clinical trials for rapamycin derivatives
  • Stay informed about developments in mTOR inhibitor research
  • Consult with healthcare professionals before considering participation

Brogevity AI can make mistakes. Check important info.

Reference Video